Meeting
2014 ASCO Annual Meeting
A phase II study of temsirolimus in previously treated advanced hepatocellular carcinoma (HCC).
Authors
Jasgit C. Sachdev
TGen - Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ
Jasgit C. Sachdev , Ahmed Y Javed , Alva Bowen Weir III, Ronald I Korn , Shannon M Gulla , Ronald G Newbold , Matthew Smeltzer , Raymond U Osarogiagbon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01567930
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4098)
DOI
10.1200/jco.2014.32.15_suppl.4098
Abstract #
4098
Poster Bd #
185
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.
First Author: Jaekyung Cheon
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH).
First Author: Choong-kun Lee
Poster
2018 Gastrointestinal Cancers Symposium
KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
First Author: Andrew X. Zhu
Poster
2017 Gastrointestinal Cancers Symposium
Detection of circulating tumor cells (CTC) using a non-EpCAM-based, high-definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on phase I and II trials of sorafenib plus temsirolimus.
First Author: Robin Kate Kelley